RedChip Companies

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the U.S. #finance #capitalmarkets #investorrelations

🚨 America’s next mineral crisis is here — and hardly anyone’s talking about it. China & Russia control global antimony supply — a critical mineral used in EVs & defense. But one company with a district-scale project in Alaska may hold the answer… and a multi-million-ounce gold deposit to boot. 🎥 Watch the latest Undiscovered Gems episode to learn more: 🔗 https://lnkd.in/e9wVnh2b Mines and Money Mining News S&P Global Commodity Insights #NovaMinerals #RedChipClient #preciousmetals #antimony #Alaska #goldrush #Gold #MiningStocks

🚀 XTI Aerospace (Nasdaq: XTIA) National Security Veteran Joins to Advance TriFan 600 Strategy XTI Aerospace has added Preston Dunlap—former Chief Architect of the U.S. Space Force and Air Force—to its Corporate Advisory Board. With oversight of $70B in aerospace programs and a track record launching $250B in next-gen defense tech, Dunlap brings unparalleled insight to support TriFan 600's path to certification and commercialization. 💡 Why This Matters for Investors: - Defense-Ready Expertise: Dunlap’s leadership aligns TriFan 600 with potential military, medevac, and homeland security use cases. - Accelerating Certification: Strategic guidance aims to fast-track market entry for this hybrid VTOL aircraft. - Dual-Use Appeal: The TriFan’s runway-free, fixed-wing efficiency positions it for both commercial and defense demand. 📄 Learn More About the Appointment: https://lnkd.in/e4TWFgWf Aerospace & Defense Technology News #AerospaceInnovation #DefenseStocks #eVTOL #NationalSecurity #AviationFuture

🚨 Connect Biopharma (Nasdaq: CNTB) to Showcase Respiratory Innovation at ATS 2025 Connect Biopharma will present four clinical posters at the American Thoracic Society 2025 International Conference, spotlighting promising data for its lead candidate rademikibart, a next-gen IL-4Rα antibody for asthma and COPD. 🧬 Why This Matters to Investors: - Strong Clinical Data: Phase 2b data shows rapid, clinically meaningful lung function improvement—FEV₁ gains seen within 24 hours. - Addressing Large, Unmet Need: Targeting acute exacerbations in ~2.3M U.S. asthma and COPD patients annually—an underserved, high-need market. - Upcoming Milestone: Connect Biopharma's parallel Phase 2 trials set to begin in Q2 2025, accelerating rademikibart’s path through the clinic. 📄 Full press release and presentation details: 🔗 https://lnkd.in/e_CS96Wk Asthma.net Biotechnology Biotechnology News #CNTB #Asthma #COPD #Biotech #ClinicalTrials #RespiratoryCare #Investing #finance

Nexalin Technology (Nasdaq: NXL) Launches Anxiety and Chronic Insomnia Study in Brazil Nexalin Technology has received IRB approval to launch a Phase II clinical trial in Brazil using its Gen-2 neurostimulation device to treat anxiety disorders and chronic insomnia—conditions that affect millions and often occur together. Why This Matters to Investors: - Global Expansion: Nexalin Technology's first IRB-approved study in Latin America, expanding its international clinical footprint. - Strategic Partnership: Conducted at IPq-HCFMUSP, one of Latin America’s leading psychiatric research centers. - Strong Leadership: Study led by globally recognized neuromodulation expert Dr. Andre Brunoni. Results are expected to be published in a peer-reviewed journal—potentially opening doors to new regulatory approvals and commercialization pathways. https://lnkd.in/ehUcpu5J Neuroscience News Neurostimulation Biotechnology #Nexalin #RedChip #RedChat #Biotech #MentalHealth #PTSD #FinancialNews #Investing

ASP Isotopes (Nasdaq: ASPI) to List on Johannesburg Stock Exchange – Expanding Global Investor Access ASP Isotopes has announced plans for a secondary listing on the JSE, marking a major milestone in its South African-rooted growth journey. The listing aims to enhance liquidity, diversify the shareholder base, and unlock new capital opportunities in a key market for the company. Why This Matters for Investors: - Strategic Expansion: Builds on ASP Isotopes' deep operational footprint in South Africa, where 97% of staff and all production facilities are based. - Tech-Driven Growth: Commercial production underway for isotopes critical to quantum computing, semiconductors, and nuclear medicine. - Broader Market Access: JSE listing opens the door to South African institutional capital and investor participation. Learn more about the planned listing and ASP Isotopes' global growth strategy: https://lnkd.in/e9huiYRM Nuclear S&P Global Commodity Insights #RedChip #RedChat #ASPIsotopes #NuclearEnergy #Isotopes #Sustainability #Investing #GreenTech

📣 Investor Webinar Today: Calidi Biotherapeutics (NYSE American: CLDI) Showcases Strategic Vision with New CMO Calidi Biotherapeutics invites investors to a live webinar today at 4:15 PM EST, featuring newly appointed Chief Medical Officer, Dr. Guy Travis Clifton—a seasoned surgical oncologist with 17+ years in cancer immunotherapy and translational clinical trials. 🧬 Calidi is advancing two clinical-stage immunotherapy platforms: - CLD-101: Stem cell-based virotherapy targeting high-grade gliomas. - CLD-201: Enveloped virotherapy platform for solid tumors, with a dose escalation trial underway. 💡 Why This Matters to Investors: - Dr. Clifton’s appointment signals strengthened clinical leadership as Calidi Biotherapeutics prepares for its next phase of growth. - Proprietary delivery platforms offer potential in treating—and preventing—metastatic cancer. 🎯 Don’t miss this opportunity to hear about Calidi's clinical progress and long-term strategy firsthand. 🔗 https://lnkd.in/exT96W7M California Institute for Regenerative Medicine (CIRM) Northwestern University City of Hope The Lancet Group #RedChip #RedChat #CalidiBio #BiotechStocks #Oncology #InvestorUpdate #CancerResearch #FinancialNews

🧬 Still Undervalued? Aptevo (Nasdaq: APVO) May Be Flying Under the Radar December data from Aptevo Therapeutics Inc's AML program showed 100% remission in Cohort 1 patients—driven by mipletamig (APVO436), a CD123 x CD3 bispecific immunotherapy targeting high-risk AML. 🔬 Why This Matters Now: ✅ 2 of 3 Patients Achieved MRD-Negativity ✅ Includes a Response in TP53+ Patient ✅ Cohort 2 Is Now Enrolling—next dataset could be pivotal 📄 Learn more: https://lnkd.in/eDY42P5G Biotechnology Biotechnology News #BiotechStocks #AML #ClinicalTrials #CancerResearch #Aptevo #APVO #Oncology

Gold recently cleared $3,400/oz all-time highs. With significant resources in the ground in Alaska and growing antimony exposure, Nova Minerals Limited (Nasdaq: NVA) is one of the few juniors aligned with both macro momentum and strategic metals demand. Learn more: https://lnkd.in/eVVMfT4u Mines and Money S&P Global Commodity Insights Commodities: Iron, Steel, Copper, Metal, Gold, Silver, Rice, Wheat, Oil, Gas, Coffee, Cotton, Sugar #NovaMinerals #RedChipClient #RedChat #preciousmetals #antimony #Alaska #goldrush #Gold #MiningStocks 

📣 Happening Today: BullFrog AI (Nasdaq: BFRG) Hosts Investor Webinar at 4:15 PM EST BullFrog AI invites investors to a live webinar today at 4:15 PM EST to explore how its proprietary AI platform, bfLEAP®, is reshaping drug discovery for biopharma companies. 💡 Why Tune In: - AI That Delivers: Learn how BullFrog Data Networks® empowers drug developers to identify targets faster, repurpose therapies, and optimize clinical trials—at a fraction of traditional costs. - Market-Driven Strategy: With R&D spending topping $200B annually, $BFRG offers scalable tools to improve success rates and reduce development timelines. - Investor-Focused Growth: Hear directly from leadership about upcoming catalysts, revenue streams, and partnerships with top-tier research institutions. 🔗 https://lnkd.in/eVt344HH Biotechnology Biotechnology News #BullfrogAI #RedChip #RedChat #AI #BiotechStocks #BFRG #DrugDiscovery #Nasdaq #Innovation #Investing